Atlas Arteria Earnings Calls
| Release date | Feb 25, 2026 |
| EPS estimate | $0.200 |
| EPS actual | $0.197 |
| EPS Surprise | -1.45% |
| Revenue estimate | 93.682M |
| Revenue actual | 55.048M |
| Revenue Surprise | -41.24% |
| Release date | Aug 27, 2025 |
| EPS estimate | $0.120 |
| EPS actual | $0.0485 |
| EPS Surprise | -59.60% |
| Revenue estimate | 115.405M |
| Revenue actual | 50.776M |
| Revenue Surprise | -56.00% |
| Release date | May 15, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Feb 27, 2025 |
| EPS estimate | $0.168 |
| EPS actual | $0.0946 |
| EPS Surprise | -43.53% |
| Revenue estimate | - |
| Revenue actual | 46.668M |
Last 4 Quarters for Atlas Arteria
Below you can see how MAQAF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 27, 2025 |
| Price on release | $3.00 |
| EPS estimate | $0.168 |
| EPS actual | $0.0946 |
| EPS surprise | -43.53% |
| Date | Price |
|---|---|
| Feb 21, 2025 | $3.00 |
| Feb 24, 2025 | $3.00 |
| Feb 25, 2025 | $3.00 |
| Feb 26, 2025 | $3.00 |
| Feb 27, 2025 | $3.00 |
| Feb 28, 2025 | $3.00 |
| Mar 03, 2025 | $3.10 |
| Mar 04, 2025 | $3.10 |
| Mar 05, 2025 | $3.10 |
| 4 days before | 0% |
| 4 days after | 3.33% |
| On release day | 0% |
| Change in period | 3.33% |
| Release date | May 15, 2025 |
| Price on release | $3.57 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| May 09, 2025 | $3.57 |
| May 12, 2025 | $3.57 |
| May 13, 2025 | $3.57 |
| May 14, 2025 | $3.57 |
| May 15, 2025 | $3.57 |
| May 16, 2025 | $3.57 |
| May 19, 2025 | $3.57 |
| May 20, 2025 | $3.57 |
| May 21, 2025 | $3.57 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Aug 27, 2025 |
| Price on release | $3.50 |
| EPS estimate | $0.120 |
| EPS actual | $0.0485 |
| EPS surprise | -59.60% |
| Date | Price |
|---|---|
| Aug 21, 2025 | $3.50 |
| Aug 22, 2025 | $3.50 |
| Aug 25, 2025 | $3.50 |
| Aug 26, 2025 | $3.50 |
| Aug 27, 2025 | $3.50 |
| Aug 28, 2025 | $3.50 |
| Aug 29, 2025 | $3.05 |
| Sep 02, 2025 | $3.50 |
| Sep 03, 2025 | $3.50 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Feb 25, 2026 |
| Price on release | $3.68 |
| EPS estimate | $0.200 |
| EPS actual | $0.197 |
| EPS surprise | -1.45% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $3.39 |
| Feb 20, 2026 | $3.39 |
| Feb 23, 2026 | $3.39 |
| Feb 24, 2026 | $3.68 |
| Feb 25, 2026 | $3.68 |
| Feb 26, 2026 | $3.68 |
| Feb 27, 2026 | $3.68 |
| Mar 02, 2026 | $3.68 |
| Mar 03, 2026 | $3.68 |
| 4 days before | 8.55% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 8.55% |
Atlas Arteria Earnings Call Transcript Summary of Q4 2025
Atlas Arteria reported steady operational performance in FY2025 with proportional toll revenue up 9.4% and proportional EBITDA up 9.3%, driven by traffic growth (notably France and Dulles Greenway), CPI-linked toll increases and favorable FX movements. Free cash flow per security was slightly down, mainly due to France's Temporary Supplemental Tax (TST). The board confirmed a distribution of $0.40 per security for 2025 and announced the same $0.40 distribution guidance for 2026. Management highlighted a refreshed leadership structure and a clarified strategy built on four pillars: strategy (portfolio optimization), partnerships, disciplined development (prioritizing distribution-accretive opportunities), and capital management. Key near-term focuses are unlocking value at existing assets (including Dulles Greenway rate-case activities), preparing for future French concession retenders (noting evolving concession size/duration and tax framework), disciplined pursuit of new OECD opportunities that complement the portfolio, and maintaining an optimal capital structure. The group maintains a strong corporate cash balance (~$151m) and active FX hedging on part of euro distributions (zero upfront cost, rolling 12-month program). Management expects growth-related corporate costs of roughly $5–10m p.a. over the next 2–3 years (funded from corporate cash), and sees capacity to return to their 90–110% free cash flow payout range once the TST impact abates. The balance sheet remains robust with $1.4bn of bonds issued across businesses in 2025 and ongoing refinancing assessment for 2026.
Sign In
Buy MAQAF